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predominantly treated by conventional insulin therapy reporting high rates of severe hypoglycaemia and high levels of HbA 1 c [4] [5] [6] . Other diabetes centres have shown that intensification of insulin therapy was not associated with an increased risk of severe hypoglycaemia [7] [8] [9] [10] [11] [12] [13] [14] [15] . These differences between centres cannot be simply explained by differences in the achieved degree of metabolic control, the definition and ascertainment of severe hypoglycaemia or patient characteristics [15] . Hence, these studies suggest that intensified insulin therapy is not necessarily associated with a high risk of severe hypoglycaemia, and that conventional insulin therapy does not necessarily protect from an excessively high risk of severe hypoglycaemia. In addition, in the DCCT, among the intensively treated patients less than 10 % of the variation in severe hypoglycaemia (using time intervals as the dependent variable) could be explained by patient characteristics including HbA 1 c levels [16] . In fact, the DCCT supports the assumption that patient related factors and hypoglycaemia ascertainment cannot explain the centre-effect, since in this trial all of these variables had been standardized. Rather, the centre effect might be due to differences in the performance of intensified insulin therapy, including differences in the strategies of insulin substitution, objectives, contents, intensity and quality of diabetes education, and health beliefs and attitudes of the health care team towards usefulness and safety of intensified insulin therapy. In the DCCT, insulin therapy and patient education were not standardized. Meta-analyses on intensified insulin therapy conceal possibly important differences with respect to treatment and teaching methods and overall diabetes care performance between centres [2, 17] .
In our recent multicentre study including a large cohort of 636 insulin-dependent diabetic (IDDM) patients intensification of insulin therapy was associated with both a decrease in HbA 1 c levels and a decrease in the risk of severe hypoglycaemia [10] . At baseline, all patients had participated in the same comprehensive and structured treatment and teaching programme in one of the 10 participating centres. The aim of the present analysis was to describe the association between HbA 1 c levels and the incidence of severe hypoglycaemia in this group of patients and to identify potential predictors of severe hypoglycaemia during a 6-year follow-up period.
Subjects and methods
The study population consists of 636 IDDM patients (81 % of the original cohort of 784 consecutively referred patients) who had taken part in a German multicentre intervention trial which documented the feasibility to translate a treatment and teaching programme for intensification of insulin therapy (ITTP) from a specialized University diabetes centre to general internal medicine hospitals [10] , and who were re-examined after 1, 2, 3 and 6 years. Since the outcome was not significantly different for the specialized centre and the nine participating general hospitals, for the purpose of the present study the combined group of 636 patients was analysed. Detailed descriptions of the study population, the ITTP, translation of the ITTP, medical care of the patients after discharge, evaluation protocols, drop outs, and results for up to 6 years have been published [10, [18] [19] [20] . In short, patients with IDDM were considered eligible for recruitment if they fulfilled the following criteria: age between 15 and 40 years, absence of advanced diabetic late complications (serum creatinine > 177 m mol/l; blindness), residence within 100 km from the respective hospital. A history of repeated or unexplained severe hypoglycaemia was not an exclusion criteria. After discharge patients were primarily followed up by their family physician [10] .
The objectives of the 5-day in-patient group ITTP were to enable patients to improve glycaemic control without increasing the risk of severe hypoglycaemia and to liberalize the diet [10, 15, 18] . Patients were advised to measure blood glucose before main meals and at bedtime and to inject NPH insulin in the morning and at bedtime and regular insulin before meals. Day-to-day adaptation of insulin dosages by the patients themselves according to blood glucose values and varying amounts of carbohydrate intake was considered a prerequisite for achieving the treatment goals. The teaching was delivered by a nurse educator and a dietitian in a structured programme which is based on a written curriculum including learning objectives and teaching methods [21] .
The follow-up examinations were performed by four trained investigators, who had not been involved in the care of the patients [10, [18] [19] [20] . Severe hypoglycaemia was defined as a self-reported episode of hypoglycaemia necessitating treatment with intravenous glucose or glucagon injection. Using this definition of severe hypoglycaemia, recording of blood glucose values was not mandatory. Severe hypoglycaemia was assessed at each examination retrospectively for the preceding year [10] . The reference range for HbA 1 c levels as measured by the Diamat HPLC-method (Biorad, Mü nchen, Germany) is 4.3-6.1 % [18, 19] . Random C-peptide levels were measured using a human C-peptide assay (Behring, Marburg, Germany). A value of less than 0.1 nmol/l was considered negative.
As potential predictors of severe hypoglycaemia during the follow-up period the following variables were considered: 1) Baseline demographic data: gender, age, diabetes duration, age at onset of diabetes; 2) Diabetes-related parameters: mean ( = mean of values assessed at 1, 2, 3, and 6 years of follow-up) HbA 1 c during the follow-up period, severe hypoglycaemia during the year preceding the ITTP, insulin dose (IU/kg body weight), percentage of regular insulin of total daily insulin dose, and C-peptide levels at the 1-year follow-up, and centre in which the ITTP was performed. 3) Psychosocial and behaviour-related parameters at the 1-year follow-up: diabetesrelated knowledge using a validated questionnaire with 39 items [22, 23] , emotional coping using a validated subscale of the ATT39 test [19, [23] [24] [25] , and compliance to carrying emergency carbohydrates for the treatment of hypoglycaemia.
To identify variables which are able to predict prospectively the long-term risk of severe hypoglycaemia treatment related, behavioural and psychosocial variables at the 1-year followup were considered. The 1-year follow-up was the first occasion to assess changes in insulin treatment, knowledge, compliance and emotional coping after participation in the ITTP.
Statistical analysis.
To determine significant predictors of severe hypoglycaemia a stepwise logistic regression analysis was performed. For parameter estimation maximum likelihood methods and for significance testing Wald's chi 2 statistic were used. Parameters were regarded as significant at p less than 0.05. Changes over time within the total study population, comparing baseline values and mean values over the 6-year follow-up period were tested for statistical significance by the paired samples t-test and the Wilcoxon signed-ranks test. For comparisons of independent samples t-test, Mann-Whitney Utest and chi-square test were applied. For computations SPSS/ PC + and SAS procedure PROC LOGISTIC was used [26] [27] [28] .
Results
At baseline, mean age of the 636 patients (48 % women) was 27 ± 7 years, diabetes duration 8 ± 7 years, body mass index 22.7 ± 2.9 kg/m 2 , and HbA 1 c 8.3 ± 1.9 %. The mean HbA 1 c during follow-up was 7.6 ± 1.3 % (p < 0.001 compared to baseline). Among patients with a diabetes duration of more than 1 year at entry into the study (n = 538) 27 % had a history of severe hypoglycaemia and 15 % had experienced at least one severe hypoglycaemic episode during the year preceding the ITTP. The incidence of severe hypoglycaemia of these 538 patients decreased from 0.28 cases/patient/year during the year preceding the ITTP to 0.17 cases/patient/year during the 6-year follow-up period. Figure 1 shows the course of HbA 1 c levels and the incidence of severe hypoglycaemia at baseline and at the four follow-up examinations over 6 years. Although HbA 1 c was improved, particularly over the first 3 years of follow-up, the incidence of severe hypoglycaemia decreased from 0.28 the year preceding the programme to about 0.20 after one (p < 0.05), two (p < 0.06) and 6 years (p < 0.05) and 0.13 (p < 0.001) after 3 years. The percentage of patients who had experienced at least one episode of severe hypoglycaemia was 15 % in the year preceding the ITTP and 11, 12, 10 and 12 %, respectively after 1, 2, 3 and 6 years [10, 20] . Table 1 compares patients with at least one severe hypoglycaemic episode during follow-up and those without. Patients with at least one severe hypoglycaemia had lower mean HbA 1 c levels, a higher daily insulin dose, they had a longer diabetes duration, were younger at onset of diabetes, they had less emotional coping abilities, more of them were C-peptide negative, and they had a more than threefold higher risk of having experienced severe hypoglycaemia during the year preceding the ITTP.
In accordance with the DCCT analysis [1] , patients were divided into decile groups of mean HbA 1 c during the 6-year follow-up (Fig. 2) . In contrast to the DCCT, the present analysis revealed no exponential association between HbA 1 c and severe hypoglycaemia. Groups with mean HbA 1 c values of 5.7 % (range: 4.9-6.1 %), 7.0 % (6.9-7.1 %), 7.4 % (7.1-7.5 %), 7.7 % (7.5-7.8 %) and 8.9 % (8.6-9.3 %) had a comparable risk of severe hypoglycaemia (between 0.15 and 0.19 cases/patient/year).
The predictive value of HbA 1 c levels for the occurrence of severe hypoglycaemia during follow-up was assessed by logistic regression analysis, adjusting for demographic, disease-related, psychosocial and behavioural variables (Table 2 ). In this model, which showed an appropriate goodness-of-fit (Hosmer- Lemeshow-test; p = 0.12), a lower mean HbA 1 c during follow-up, a history of severe hypoglycaemia during the year preceding the ITTP, negative C-peptide levels, not carrying emergency carbohydrates, poorer scores on the coping scale, and a younger age at onset of diabetes were associated with a greater risk of severe hypoglycaemia during follow-up.
In order to visualize the relative importance and predictive value of the strongest explanatory variables, Figure 3 demonstrates the risk for subgroups of patients. C-peptide negative patients with at least one severe hypoglycaemia before the ITTP had the highest risk of severe hypoglycaemia, patients with no history of severe hypoglycaemia who were C-peptide positive had the lowest risk.
The centre in which the ITTP was performed (university diabetes centre vs general hospital) was not a significant predictor of the risk of severe hypoglycaemia. HbA 1 c as well as the incidence of severe hypoglycaemia were comparable during the 6-year follow-up period between the specialized centre (n = 114, 7.8 %, 0.14 cases/patient/year) and the nine general hospitals (n = 522, 7.6 %, 0.16 cases/patient/ year).
The variation in the incidence of severe hypoglycaemia during follow-up between the 10 centres was between 0.05 and 0.27 cases/patient/year (Fig. 4) . None of the centres had a higher incidence of severe hypoglycaemia during follow-up than the initial incidence of 0.28 for the whole sample.
Discussion
In this large cohort of intensively treated IDDM patients improvement of HbA 1 c levels after participation in a structured ITTP was associated with a decrease in the risk of severe hypoglycaemia, and there was no linear or exponential relationship between HbA 1 c and severe hypoglycaemia when simple group comparisons were carried out. In contrast to the DCCT, in the present study, treatment strategies as well as teaching methods were standardized and documented. Based on such a written curriculum, the ITTP as developed and evaluated at a specialized diabetes center, could be effectively and safely transferred to non-specialized hospitals. In contrast, in the DCCT feasibility study, in the intensively treated group the percentage of patients experiencing hypoglycaemic coma increased from 10 % in the year prior to enrollment to 20 % during the first year of follow-up, while there was no change in the conventionally treated group (5 vs 6 %) [29] . Incidence data including all cases of severe hypoglycaemia are not reported for the year before enrollment into the DCCT. In the present study, 15 % of patients had experienced at least one severe hypoglycaemia in the year preceding the ITTP and, although HbA 1 c was improved, the percentage decreased to 10-12 % for each year of the follow-up period.
In the DCCT, among intensively treated patients there was a strong inverse exponential relationship between HbA 1 c levels and severe hypoglycaemia by using simple group comparison [1] . However, simple group comparison may lead to under-or overestimation of the association between HbA 1 c and severe hypoglycaemia. In a previous publication of the DCCT it was reported that by applying complex regression analyses, HbA 1 c levels and other patient-related potential predictors of severe hypoglycaemia could not constitute a convincing model with which to predict hypoglycaemia among intensively treated patients [16] . Although lower HbA 1 c levels, a history of severe hypoglycaemia, a longer diabetes duration, lower stimulated C-peptide values, and higher insulin dosages were identified as predictors of severe hypoglycaemia more than 90 % of the variance remained unexplained. The DCCT model used time intervals (duration between enrollment into the study and the first episode of severe hypoglycaemia) as the dependent variable to apply a proportional hazards life table regression analysis taking account of the varying duration of follow-up in each patient.
In the present study, after adjustment for confounding variables in the regression analysis, lower HbA 1 c levels, a history of severe hypoglycaemia, negative C-peptide levels, poorer scores on the coping scale, lack of compliance to carry emergency carbohydrates and a younger age at onset of diabetes were associated with a greater risk of severe hypoglycaemia during follow-up. The population had identical follow-up periods and was divided into two subgroups: patients who experienced at least one severe hypoglycaemia during follow-up and patients who did not. For such a dichotomous dependent variable, a logistic regression model has to be applied and goodness of fit cannot be assessed in terms of explained variance. Therefore, the quality of the DCCT model and the model of the present study cannot be compared. However, predictors identified in both models are quite similar.
A lack of beta-cell responsiveness, accompanied by longer diabetes duration and higher insulin doses contribute to instability of glycaemic control [30] [31] [32] . This is in accordance with recent DCCT findings [33] . In these latter analyses, within the intensive treatment group, patients with sustained beta-cell responsiveness had a reduced risk of severe hypoglycaemia (risk reduction of 62 %) despite lower HbA 1 c levels compared to C-peptide negative patients. In addition, those patients randomized to the intensive therapy who had a diabetes duration of 5 years or less and sustained beta-cell function maintained a higher level of stimulated C-peptide over a longer period than patients on conventional treatment.
Although C-peptide was entered in the regression model, age at onset of diabetes was also a significant and independent predictor of the risk of severe hypoglycaemia. This is in accordance with previous analyses [19] indicating that patients diagnosed during adolescence had a poorer glycaemic control than other patients as adjustment to and treatment of diabetes appear particularly difficult during adolescence. It could be speculated that adolescents, especially when feeling psychologically vulnerable, tend to have a less favourable self-care behaviour, which might contribute to a higher risk of severe hypoglycaemia (e. g. excessive exercise without adjustment of insulin dosage, alcohol consumption, less frequent blood glucose self-monitoring) and maintain these detrimental strategies into adulthood [34] .
Several studies have suggested that psychosocial factors play an important role for a successful selfmanagement of diabetes by the patient [19, 35, 36] . However, the majority of intervention studies regarding self-destructive behaviour focused on patients with high HbA 1 c levels and severe hyperglycaemic symptoms [36] . The coping scale used in the present study comprised items reflecting feelings of personal responsibility for the management of diabetes (Having diabetes means accepting responsibility for your own treatment) and the ability to cope with the demands of the disease (I feel quite capable of looking after my diabetes with minimum outside help). Two items were concerned with emotional support concerning diabetes and its treatment. The predictive value of the coping scale is in accordance with our previous analyses, indicating that active coping strategies, perceptions of self-efficacy and social support are closely associated with favourable glycaemic control taking account of both HbA 1 c values and the frequency of severe hypoglycaemia [19, 23] .
Despite the similarity of predictors identified in the DCCT and in the present study, the validity of comparing different studies concerning intensified insulin therapy and the incidence of severe hypoglycaemia is weakened by differences in definitions of severe hypoglycaemia, methods of ascertainment, time intervals over which events were recorded or recalled, the populations studied, and methods of treatment. Such differences also compromise the comparability of the DCCT data and the results of the present study. Although comparable definitions of severe hypoglycaemia have been used in the DCCT feasibility study and the present study, in the DCCT the definition was subsequently extended to hypoglycaemia requiring assistance from another person. Only in the DCCT, patients with a history of repeated or unexplained severe hypoglycaemia have been excluded from intensified insulin therapy.
Theoretically, the strong exponential relationship between severe hypoglycaemia and HbA 1 c in the DCCT trial could be due to hypoglycaemia requiring assistance by another person which was not examined in the present study. However, a detailed analysis of hypoglycaemic events in the DCCT revealed that the ratio of severe hypoglycaemia requiring assistance to hypoglycaemia with coma or seizures was comparable in the conventional and intensive treatment groups [37] .
Another explanation for the different results in the DCCT and the present study might be that the structured ITTP in the 10 hospitals gave patients the opportunity to define individual treatment goals and to balance favourable HbA 1 c levels and an acceptable risk of severe hypoglycaemia [23] whereas the DCCT primarily aimed at normalization of HbA 1 c values. In the present study, analyses of subgroups of patients (quartile grouping according to HbA 1 c at baseline) revealed that patients benefit differently from participation in the ITTP [23] . Patients with high HbA 1 c levels at baseline (10.8 %) improved their glycaemic control substantially during follow-up (8.3 %) without increasing the incidence of severe hypoglycaemia (0.21 cases/patient/year before the programme, 0.15 during follow-up). Patients with good HbA 1 c levels already before participation in the ITTP (6.2 %) raised their HbA 1 c levels during follow-up (6.9 %) but decreased the incidence of severe hypoglycaemia by more than 50 % (0.34 cases/patient/year before the programme, 0.15 during followup) [23] .
The fear of severe hypoglycaemia should not deter patients and their health care providers from intensive treatment of IDDM, but the most appropriate range of HbA 1 c should be discussed with each patient considering her/his individual risk factors. Under the circumstances of the present study, improvement of HbA 1 c , e. g. from 8 to 7 % would not be associated with a substantial increase in the risk of severe hypoglycaemia (Fig. 3) . In contrast, the absolute risk depends to a much greater extent on the C-peptide level and the history of severe hypoglycaemia.
Searching for risk factors of severe hypoglycaemia, it is obviously not sufficient to consider only patient characteristics as potential predictors. Nothing is known about the impact of physician-related factors as possible explanatory variables for the overall risk of severe hypoglycaemia associated with a particular insulin therapy at a particular diabetes centre. We do not know how attitudes or health beliefs of the treating physician or the health care team influence effectiveness and safety of insulin therapy and what kind of interactions there are between these attitudes and the quality and intensity of patient training, such as to recognize early, effectively treat, and, most importantly, prevent hypoglycaemia. Such factors might, in fact, be causally related to the documented centerto-center differences concerning the risk of severe hypoglycaemia in patients on intensified insulin therapy. It would be an interesting challenge in the near future to develop a comprehensive model including a variety of potential predictors aiming to identify an increasing proportion of the variance in hypoglycaemic episodes. Apart from health care team related factors and analyses of the quality of treatment and teaching programmes, such an evaluation would have to include a systematic assessment of the patients' hypoglycaemic awareness.
